You Position: Home > Paper
Relations of farnesyltransferase beta-subunit mRNA expression with clinicopathological features and H-ras mutation in gastric cancer tissues
( views:182, downloads:8 )
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 21
- DOI:
- 10.3969/j.issn.1009-3079.2005.21.009
- Key Word:
- 胃癌;法尼基转移酶;H-ras基因;突变;聚合酶链反应
Abstract： 目的:检测人胃癌及相应癌旁组织中法尼基转移酶(FTase)β-亚单位mRNA表达和H-ras基因第12密码子点突变探讨FTaseβ-亚单位基因在胃癌中的表达与临床病理特点、H-ras基因突变的关系.方法:收集胃癌及相应癌旁正常组织标本43例.应用半定量逆转录酶-聚合酶链反应(RT-PCR)测定FTase β-亚单位mRNA基因表达水平,应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析H-ras基因第12密码子点突变情况.采用秩和检验分析胃癌和癌旁组织的FTase β亚单位mRNA表达的配对数据的差异;采用多元逐步回归分析胃癌组织中FTaseβ亚单位mRNA表达活性与临床病理特点及H-ras基因突变间的关系.结果:胃癌组织中FTase β亚单位mRNA的平均值明显高于癌旁组织(0.89±0.48 vs 0.69±0.40),两者相比有显著性差异(Z=2.469,P=0.014).在43例胃癌组织中有1例发现突变(1/43,2.3%),癌旁组织中未发现突变.胃癌组织的FTase β亚单位mRNA表达活性与年龄、肿瘤部位、组织学分级、有无淋巴结转移及有无H-ras基因突变无关,在女性,病理分型为印戒细胞癌的胃癌组织中有较高的FTase β亚单位mRNA表达活性.结论:FTase β亚单位mRNA在胃癌组织中表达升高.胃癌组织中H-ras基因第12密码子点突变率低,在胃癌的发生中不起主要作用,并且与FTase β亚单位mRNA的表达无相关.
- [1]M, Koshiba,O, Ogawa,T, Habuchi,etc.Infrequent ras mutation in human stomach cancers.[J].1993,84.
- [2]T, Nagase,S, Kawata,H, Nakajima,etc.Effect of farnesyltransferase overexpression on cell growth and transformation.[J].1999,80.
- [3]Clarke Steven.Protein Isoprenylation and Methylation at Carboxyl-Terminal Cysteine Residues[J].1992.
- [4]S G, Khan,R, Dummer,J, Siddiqui,etc.Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.[J].1996,220(3).
- [5]杨定成,徐文怀,李通,等.胃癌C-HA-RAS基因突变分析方法的建立及临床应用研究[J].1995,(1).
- [6]Phuong Khanh H. Morrow,Edward S. Kim.New Biological Agents in the Treatment of Advanced Non-Small Cell Lung Cancer[J].2005,26(3).
- [7]P F, Lebowitz,G C, Prendergast.Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.[J].1998,17.
- [8]Humblet Y,Karasek P,Post S,etc.Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer.[J].2004,22(8).
- [9]罗元辉,房殿春,鲁荣,等.采用PCR-RFLP技术分析石蜡包埋胃癌组织RAS和P53基因点突变[J].1995,(2).
- [10]K, Grünewald,J, Lyons,A, Fr?hlich,etc.High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.[J].1989,43.
- [11]T, Kihana,H, Tsuda,T, Hirota,etc.Point mutation of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation.[J].1991,82.
- [12]Carrizales G,Campos D,Patnaik A,etc.Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro.[J].2005,25(5).
- [13]Qian Y,Blaskovich MA,Sebti SM,etc.A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.[J].1995,270(2).
- [14]Demma I,Lorusso D,Bifulco M,etc.Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation.[J].2003,38(1).
- [15]B D, Cheson.Clinical trials referral resource.[J].1990,4.
- [16]G R, Deng,X H, Liu,J R, Wang.Correlation of mutations of oncogene C-Ha-ras at codon 12 with metastasis and survival of gastric cancer patients.[J].1991,6(1).